On Thursday, Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI)’s shares declined -15.12% to $7.30.
Plasmatech Biopharmaceuticals Inc (PTBI) declared that it has reached a definitive agreement with one institutional investor in a private placement of about $10 million of common stock at a price of $8.00 per share, or 1,250,000 shares.
In addition, the Company will issue to the investors warrants to purchase 625,000 shares of common stock. The warrants have an exercise price of $10.00 per share and are exercisable for 30 months from the closing date.
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company, develops protein biologic therapies and oncology supportive care products. The company’s marketed product comprises MuGard the administration of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s shares dropped -13.92% to $1.36.
AVEO Pharmaceuticals, Inc. (AVEO) stated financial results for the first quarter ended March 31, 2015.
Recent Highlights
Declared Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia – In April, AVEO declared the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly raised plasma GDF15 levels. The data were presented in a poster titled “Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody” at the 2015 Annual Meeting of the American Association of Cancer Research in Philadelphia.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
At the end of Thursday’s trade, Swift Energy Company (NYSE:SFY)‘s shares dipped -13.73% to $2.45.
Swift Energy Company (SFY) stated recently its first quarter 2015 financial and operating results.
First Quarter 2015 Results
Swift Energy produced 3.06 million barrels of oil equivalent (“MMBoe”) during the first quarter of 2015, a 4% enhance over first quarter 2014 production of 2.94 MMBoe, and up 2% contrast to fourth quarter 2014 production of 3.00 MMBoe.
Swift Energy stated an adjusted net loss for the first quarter of 2015 of $36.5 million, or $0.83 per diluted share, which excludes the non-cash ceiling test write-down of its oil and gas properties of $502.6 million.
Swift Energy Company, an independent oil and gas company, acquires, explores, develops, and operates oil and gas properties.
OraSure Technologies, Inc. (NASDAQ:OSUR), ended its Thursday’s trading session with -13.47% loss, and closed at $5.33.
OraSure Technologies, Inc. (OSUR) declared its merged financial results for the first quarter ended March 31, 2015.
Financial Highlights
- Merged net revenues for the first quarter of 2015 were $27.1 million, a 15% enhance from the comparable period of 2014.
- Net product revenues for the Company’s OraQuick(R)rapid HCV test were $2.2 million for the first quarter of 2015, representing a 39% enhance over the first quarter of 2014. Total HCV-related revenues, counting exclusivity payments recognized under the HCV co-promotion agreement with AbbVie, were $5.5 million for the first quarter of 2015, $3.9 million higher than the same period last year.
OraSure Technologies, Inc., together with its auxiliaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
